兽医心臟病市场－全球产业规模、份额、趋势、机会、预测：按动物类型、产品、适应症、最终用途、地区和竞争格局划分，2021-2031年

全球兽医心​​臟病市场预计将从 2025 年的 28.3 亿美元成长到 2031 年的 47.1 亿美元，复合年增长率为 8.86%。

这领域涵盖专门针对伴侣动物心臟病的诊断、药物和治疗方法。推动该领域发展的关键因素是老年宠物心臟病发病率的上升以及人类与动物之间情感纽带的日益加深。这促使饲主越来越倾向寻求先进的医疗服务。根据美国宠物用品协会 (APPA) 预测，到 2024 年，兽医护理及相关产品的支出预计将达到 398 亿美元，这将形成一个强大的经济基础，使兽医诊所能够投资于心臟病服务和先进的诊断技术。

儘管存在一些积极因素，但由于专业心臟治疗费用高昂，市场仍面临许多障碍。购买先进的心臟超音波图设备需要大量投资，加上复杂手术的费用，往往令预算有限的宠物饲主望而却步。这些经济障碍缩小了潜在患者群体，并可能阻碍高端心臟治疗方案的普及，尤其是在价格敏感的地区。

市场驱动因素

兽医心臟影像影像技术的进步正在推动产业变革，使复杂心臟疾病的早期精准识别成为可能。超音波心动图、心电图监测和生物标记分析等领域的现代创新，使兽医能够在症状恶化之前诊断出诸如二尖瓣疾病等病症。此外，人工智慧辅助技术的引入也有助于加速临床决策和设备应用。 IDEXX Laboratories 2024 年 10 月的数据显示，该公司全球高阶设备的部署量年增 10%，印证了这一趋势。此外，Nationwide 2024 年 4 月的报告指出，瓣膜性心臟病是犬隻第八大常见疾病，凸显了精准检测能力的重要性。

宠物保险覆盖范围的扩大也有助于宠物主人更便捷地获得专科护理，为面临长期心臟病治疗高昂费用的饲主提供至关重要的经济保障。随着保险单越来越涵盖专科转诊和慢性疾病，饲主可以更容易获得以前难以负担的维持生命的治疗，例如心臟起搏器和终身服药。这种覆盖范围的扩大直接增加了专科诊所和製药公司的收入。根据北美宠物健康保险协会2024年4月发布的报告显示，2023年该行业保费总额达到42.7亿美元，显示用于高级兽医护理的资金显着增加。

市场挑战

全球兽医心​​臟病市场面临的最大障碍是专业心臟护理服务的高昂费用。购买诸如超音波心动图等先进诊断设备和进行复杂手术需要大量投资，这迫使兽医诊所收取高额费用，加重了饲主的经济负担。这种经济压力使得专业的心臟病治疗难以负担，尤其是在宠物保险覆盖率低的地区以及可支配收入有限的个人。

这些经济壁垒直接限制了目标市场，阻碍了高品质心臟病解决方案的广泛应用。当治疗费用超出饲主的预算时，他们被迫推迟或放弃必要的治疗，导致心臟病服务量下降。根据美国兽医协会（AVMA）预测，到2024年，宠物就诊量将下降2.3%，主要原因是价格上涨。这一降幅表明，不断上涨的成本正在有效地将部分市场拒之门外，并阻碍了该行业的成长潜力。

市场趋势

微创介入手术的兴起正在革新市场，为高风险的开胸手术提供了更安全的导管介入替代方案。兽医越来越多地采用经导管缘对缘修復等先进技术来解决二尖瓣疾病等复杂问题，从而减轻老年宠物的身体负担并缩短康復时间。这种向更先进治疗方法的转变正显着增加专科护理的频率和成本。 Trupanion 于 2025 年 7 月发布的一份报告强调了市场对这些先进介入服务的强劲需求，预计犬类心臟病相关的保险索赔将激增 55%，平均索赔额将增长 34%。

同时，远距心臟病学和远距会诊服务的蓬勃发展，正透过为全科医生提供与心臟病专家无缝对接的途径，帮助弥合诊断差距。这种模式依赖于整合云端系统，能够即时共用心电图和超音波心动图数据以供专家审核，但这需要对数位基础设施进行大量投资。这种互联医疗模式的进步正直接提升技术提供者的收入。例如，IDEXX Laboratories 报告称，截至 2025 年 2 月，其兽医软体、服务和诊断影像业务的收入增长了 13%，这凸显了数位平台在不断发展的远端心臟病诊断领域中发挥的关键作用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球兽医心​​臟病市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 动物种类（伴侣动物、生产动物）
  • 依产品类型（药品、诊断试剂）
  • 适应症（郁血性心臟衰竭、心肌病变、心律不整等）
  • 按用途（兽医院/诊所，其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美兽医心臟病市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲兽医心臟病市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区兽医心臟病市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲兽医心臟病市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲兽医心臟病市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球兽医心​​臟病市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Boehringer Ingelheim International GmbH
• Jurox Pty Limited
• Ceva Animal Health, LLC
• Merck & Co., Inc.
• IDEXX
• Apex Bio Medicals
• SOUND
• GE HealthCare
• FUJIFILM Holdings America Corporation
• ESAOTE SPA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Cardiology Market is projected to expand from USD 2.83 Billion in 2025 to USD 4.71 Billion by 2031, registering a CAGR of 8.86%. This sector encompasses specialized diagnostics, pharmaceuticals, and therapies aimed at detecting and treating heart conditions in companion animals. Growth is largely fueled by the increasing prevalence of cardiac issues in aging pets and the strengthening emotional bond between humans and animals, which encourages owners to pursue advanced medical care. According to the American Pet Products Association, spending on veterinary care and products hit $39.8 billion in 2024, creating a solid economic base that allows clinics to invest in cardiac services and modern diagnostics.

Despite these positive indicators, the market confronts a major obstacle due to the significant expenses involved in specialized cardiac care. The substantial investment needed for advanced echocardiography equipment, combined with the costs of complex surgeries, often restricts access for pet owners with limited budgets. These economic hurdles narrow the potential patient pool and threaten to stall the broader adoption of high-end cardiology solutions, particularly in areas where price sensitivity is high.

Market Driver

Advancements in technology for veterinary cardiac imaging and diagnostics are reshaping the industry by facilitating the earlier and more precise identification of complex heart disorders. Modern innovations in echocardiography, ECG monitoring, and biomarker analysis allow vets to diagnose conditions like mitral valve disease before symptoms escalate, while the addition of AI support improves clinical decision-making and equipment adoption. Data from IDEXX Laboratories in October 2024 highlighted a 10% annual increase in their global premium instrument installed base, illustrating this trend. Furthermore, a Nationwide report from April 2024 identified valvular heart disease as the eighth most common condition in dogs, underscoring the necessity for such accurate detection capabilities.

The broadening scope of pet insurance is also enhancing access to specialty care, acting as a crucial financial buffer for owners dealing with the high costs of long-term heart management. As policies increasingly cover specialist referrals and chronic conditions, owners are better positioned to afford life-extending treatments like pacemakers or lifelong medication that were once financially out of reach. This expanded coverage directly boosts revenue for specialty clinics and drug manufacturers. As reported by the North American Pet Health Insurance Association in April 2024, the industry saw $4.27 billion in total premiums in 2023, signaling a significant rise in available funds for advanced veterinary healthcare.

Market Challenge

The most significant hurdle facing the Global Veterinary Cardiology Market is the prohibitive cost associated with specialized cardiac services. Because veterinary practices must invest heavily to acquire advanced diagnostic tools like echocardiography systems and perform complex interventions, they are compelled to charge higher fees, placing a strain on pet owners. This financial pressure renders specialized cardiac procedures unattainable for many, particularly in areas with low pet insurance coverage or for individuals with limited disposable income.

These economic barriers directly constrain the addressable market and hinder the widespread uptake of premium cardiology solutions. When treatment costs surpass an owner's budget, they are often forced to delay or refuse essential care, leading to a reduction in the volume of cardiac services rendered. According to the American Veterinary Medical Association, veterinary practices saw a 2.3% drop in patient visits in 2024, largely due to rising prices. This decline demonstrates how escalating costs effectively block a portion of the market from accessing services, thereby impeding the sector's growth potential.

Market Trends

The rise of minimally invasive interventional procedures is revolutionizing the market by offering safer, catheter-based options instead of high-risk open-heart surgeries. Veterinarians are increasingly utilizing advanced methods, such as transcatheter edge-to-edge repair, to manage complex issues like mitral valve disease, resulting in less trauma and faster recovery for aging pets. This shift toward premium modalities is driving a noticeable increase in both the use and cost of specialized care. A July 2025 report by Trupanion noted that cardiology claims for dogs jumped by 55%, with the average claim value rising by 34%, highlighting the strong market movement toward these sophisticated interventional services.

Concurrently, the growth of tele-cardiology and remote consulting services is helping general practitioners bridge diagnostic gaps by providing seamless access to cardiac specialists. This model depends on integrated cloud-based systems that allow for the instant sharing of ECG and echocardiogram data for expert review, requiring significant investment in digital infrastructure. The push for this connected care model is directly boosting revenue for technology providers. For instance, IDEXX Laboratories reported in February 2025 that revenue from veterinary software, services, and diagnostic imaging grew by 13%, emphasizing the vital role digital platforms play in the expanding tele-cardiology landscape.

Key Market Players

• Boehringer Ingelheim International GmbH
• Jurox Pty Limited
• Ceva Animal Health, LLC
• Merck & Co., Inc.
• IDEXX
• Apex Bio Medicals
• SOUND
• GE HealthCare
• FUJIFILM Holdings America Corporation
• ESAOTE SPA

Report Scope

In this report, the Global Veterinary Cardiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Cardiology Market, By Animal Type

• Companion Animals
• Production Animals

Veterinary Cardiology Market, By Product

• Pharmaceuticals
• Diagnostics

Veterinary Cardiology Market, By Indication

• Congestive Heart Failure
• Myocardial Disease
• Arrythmias
• Others

Veterinary Cardiology Market, By End Use

• Veterinary Hospitals & Clinics
• Others

Veterinary Cardiology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Cardiology Market.

Available Customizations:

Global Veterinary Cardiology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Cardiology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Companion Animals, Production Animals)
  • 5.2.2. By Product (Pharmaceuticals, Diagnostics)
  • 5.2.3. By Indication (Congestive Heart Failure, Myocardial Disease, Arrythmias, Others)
  • 5.2.4. By End Use (Veterinary Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Cardiology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Product
  • 6.2.3. By Indication
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Cardiology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Veterinary Cardiology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Veterinary Cardiology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By End Use

7. Europe Veterinary Cardiology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Product
  • 7.2.3. By Indication
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Cardiology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Veterinary Cardiology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Veterinary Cardiology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Veterinary Cardiology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Veterinary Cardiology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By End Use

8. Asia Pacific Veterinary Cardiology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Product
  • 8.2.3. By Indication
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Cardiology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Veterinary Cardiology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Veterinary Cardiology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Veterinary Cardiology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Veterinary Cardiology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Veterinary Cardiology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Product
  • 9.2.3. By Indication
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Cardiology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Veterinary Cardiology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Veterinary Cardiology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By End Use

10. South America Veterinary Cardiology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Product
  • 10.2.3. By Indication
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Cardiology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Veterinary Cardiology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Veterinary Cardiology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Cardiology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Jurox Pty Limited
• 15.3. Ceva Animal Health, LLC
• 15.4. Merck & Co., Inc.
• 15.5. IDEXX
• 15.6. Apex Bio Medicals
• 15.7. SOUND
• 15.8. GE HealthCare
• 15.9. FUJIFILM Holdings America Corporation
• 15.10. ESAOTE SPA

16. Strategic Recommendations

17. About Us & Disclaimer